Its easy to buy, but try to sell at a profit.

The neat thing about this deal from the Chinese perspective is that since the windmills are manufactured in China they are paying their own people to produce them.

When Abraham Lincoln was advised that railroad tracks could be purchased more cheaply from Europe than from American companies he replied, "If we purchase them from American companies we get the tracks and also get to keep the money."

From what I understand, the factory in China is capable of producing as many windmills as can be sold. There shouldn't be any constraints from that end.

Here's your news:

Dakshidin Corporation Is Pleased to Announce That "Open House" Presentation of Dakshidin MARK 10 Windmill by Wuhan City Govt. (China) to Other Chinese Governments Expected to Generate Significant Additional Sales

LAS VEGAS, NV, Mar 11, 2009 (MARKET WIRE via COMTEX) -- Dakshidin Corporation (PINKSHEETS: DKSC), (FRANKFURT: 4LQ) are producers of the world's most powerful water-pumping windmill.
As a direct result of the test windmill greatly exceeding performance expectations, the Wuhan government has (as stated in the press release of Feb. 19, 2009) already decided to purchase further MARK 10 water-pumping windmills immediately. They are now planning a ceremony to take place in Wuhan City within the next fiscal quarter, inviting other government officials from nearby cities and the agricultural industry to attend.

The current drought condition in China has greatly increased the pressure on the Chinese government for an immediate solution and is expected to accelerate their windmill purchasing schedule. As their intent was to purchase a higher quantity of water-pumping windmills from DKSC in the near future, upcoming orders are anticipated to be a minimum of 500 water-pumping windmills for Wuhan City alone.

The Wuhan City government has also requested DKSC to arrange a trip to Canada and the USA for them within the next months. The purpose of this trip is to visit Dakshidin's head-office in the USA in order to meet and discuss technical support and enhancement of the products with our engineering consultants.

While the Chinese Government officials are visiting North America, DKSC will also arrange for them to meet with both institutional and private investors in order to enhance their understanding of DKSC's present and future business endeavors.

>>>'spect GTC will go up tomorrow... long-time holders like OB are selling.<<<

Good point go seek. Long-time holder capitulations have often been a significant signal in my most incredible calls of stock bottoms......although I can't think of any particular ones at the moment. ;^)

I'm with you in expecting the drop to stop.
foggy

I'm here and watching it closely.

I was told a successful test of the windmill in Wuhan could result in 250 sales.

Let that news hit and see where we go.

We should be getting word of the LFB-LEO transfer soon. It was supposed to happen by the end of the year. Management's attention was probably diverted by preparations for the panel up until now.

>>>The deal is bad for GTCB, and it is bad for shareholders, the only thing that can change this is if they pay the loan off before LFB pulls the trigger.<<<

If they weren't able to repay the loan....
and if they didn't want LFB to have controlling interest....
couldn't they dilute LFB out of control? Say, issue 70 million shares in a private offering?....or maybe a rights offering to existing shareholders before LFB was able to convert their shares?

I'm just throwing that out for the heck of it. I have confidence in Cox and gang to bring us through in style. :^)

Thanks Flo.

Hopefully we'll be hearing news of the LFB transition any day now.
I've never been a big fan of LEO as a partner and I imagine they are dragging their feet to the bitter end.

Does anybody know the price of plasma derived antithrombin in Europe?

Knowing whether it is higher, lower or equal to the price of Atryn would go a long way to resolving the 'Atryn doesn't sell in Europe' argument.

>>>Dew remarked that LEO set the price high for HD, which was
not going to generate much revenue in any case, in order to
prospectively capture higher margins in AD.<<<

Good points Lewis.

LEO setting the price high certainly wasn't in the best interest of cash strapped GTCB.
I would have been more inclined to spotlight the cost effectiveness of the new production platform and set the price of the first product much lower. Profit margins could be increased as the approved indications, and demand, grew.

Maybe LFB and Ovation will use different strategies than the foot dragging LEO. It could be a different ballgame.

How does Atryn's pricing in Europe compare to the competition?

I believe Atryn costs about $20,000 a dose. How much is a dose of plasma derived product?

If the prices are similar it isn't surprising Atryn hasn't gained much market share. This would change if LFB lowers the price, or if future approvals (chilbirth?) increase demand beyond the ability of plasma derived antithrombin's ability to supply the need.

Also, I remember reading somwhere that the US has more restrictive regulations regarding the use of plasma derivatives than does Europe. If this is true, it would be difficult to accurately use European sales to forecast US sales.

I have the impression that GTCB would like the approval process of Atryn to proceed without the hoopla that might be caused by publicizing the transgenic goat angle.

Thanks for fighting for us Jesse.

>>>I don't think it will happen because in the recent past no one outside of LFB is interested enough in GTC to put in money.<<<

Nobody was interested in what Wilbur and Orville were doing either....until the damn thing flew!

I'm willing to wait to see what happens after approval.

Based on curret valuation I am upgrading GTCB to a strong buy.

Recent capitulations mark today as the bottom.

Don't be surprised if we encounter some resistance around 1.20.

good luck,
foggy

What's the peanuts price?
--------------------------------------------------------------

Antigenics to purchase Aronex Pharmaceuticals for 1.38 times revenue

http://www.highbeam.com/doc/1P3-72546940.html

OK... here's the Jeopardy answer of the day?

GTCB HITS IT OUT OF THE PARK (PHARM)... a HOMERUN!

What is the headline?
Don't forget to answer in the form of a question or you lose.
--------------------------------------------------------------

What is...The FDA today announced the approval of Atryn for hereditary antithrombin deficiency and also announced that since Atryn, being a protein, is not really a drug and is so close chemically to naturally occuring ATIII, that it doesn't need to undergo further testing and approval for all the multitude of uses that studies have proven AtIII to be beneficial for?

A lot of times the quote will be in green.

A public company would have difficulty explaining an overly large premium to their shareholders. A private company can pay whatever they value the purchase to be.

My guess is somebody got hit with a forced margin call. The brokerage doesn't care what price they get.

Dew,

Thank you for the transcript. Everything I try has sound; except GTCB conference calls.

How do you know this?

Are you saying sales are smaller than anticipated?

He could give some insight into Atryn sales in Europe.

This was on the FreeRealTime site:


Apr 29, 2008 (Wall Street Horizon via COMTEX) --

GTC Biotherapeutics Inc. (GTCB) Expected next earnings release:
Announcement date: 5/1/2008 - Before Market
Earnings Quarter: Q1
Announcement Status: Unconfirmed

http://quotes.freerealtime.com/rt/frt/N?symbol=GTCB&art=C2008042900120c3555&SA=Latest%20News

Our attempts to fully comprehend the possible meanings of the word 'few' should not exclude its use as an exclamation...as in

"Few! Who cut the cheese?"

We're less than 3 weeks away from first quarter earnings. I'm beginning to suspect we won't hear about the partnership until the week of the conference call.

8 weeks can be a few....right?

Thanks. Much appreciated.

back to lurking,
foggy

Does IH have an ignore feature? Yahoo's has proven useful in the past.

TIA,
foggy

Up until recently this coiled spring has been acting more like a slinky walking down the stairs.

Here is to better days...

Thanks for the link medchal.

Wouldn't there have to be an announcement that trading has been halted?

Its probably just the boardmembers cousins buying at this point.
Wait til the news comes out to see the real action.

Wouldn't it be a hoot if you were both right; down big early and finishing up at the end.

Something like GTCB's action last Friday would fit my scenario.

I like definitions:

The SPA is a process that provides for an official FDA evaluation of Phase III clinical study protocols. The SPA provides trial sponsors with binding written agreement that the design and analysis of the studies are adequate to support a license application submission if the study is performed according to the SPA and the results are successful. The SPA agreement may only be changed by the sponsor company or the FDA by a written agreement, or if the FDA becomes aware of a substantial scientific issue essential to product efficacy or safety.

Is there not still a huge cost difference between building production facilities for cell based and goat based?

Also, don't the goats produce far more of the proteins from a samll herd than can be produced in cell based production?...and can't it be produced faster and cheaper?

I think the advantages of GTCB are still very great over current platforms.